Protagonist Therapeutics (PTGX) Stock Forecast, Price Target & Predictions
PTGX Stock Forecast
Protagonist Therapeutics stock forecast is as follows: an average price target of $50.00 (represents a 23.00% upside from PTGX’s last price of $40.65) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
PTGX Price Target
The average price target for Protagonist Therapeutics (PTGX) is $50.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $50.00 to $50.00. This represents a potential 23.00% upside from PTGX's last price of $40.65.
PTGX Analyst Ratings
According to 5 Wall Street analysts, Protagonist Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for PTGX stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Protagonist Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 12, 2024 | Douglas Tsao | H.C. Wainwright | $50.00 | $45.08 | 10.91% | 23.00% |
| Jun 17, 2024 | Douglas Tsao | H.C. Wainwright | $38.00 | $32.86 | 15.64% | -6.52% |
The latest Protagonist Therapeutics stock forecast, released on Sep 12, 2024 by Douglas Tsao from H.C. Wainwright, set a price target of $50.00, which represents a 10.91% increase from the stock price at the time of the forecast ($45.08), and a 23.00% increase from PTGX last price ($40.65).
Protagonist Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $50.00 | $44.00 |
| Last Closing Price | $40.65 | $40.65 | $40.65 |
| Upside/Downside | -100.00% | 23.00% | 8.24% |
In the current month, the average price target of Protagonist Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Protagonist Therapeutics's last price of $40.65. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 14, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 24, 2024 | Cowen & Co. | - | Buy | Initialise |
| Sep 12, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 07, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 24, 2024 | BTIG | Buy | Buy | Hold |
| Jun 17, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 06, 2023 | JMP Securities | Market Outperform | Market Outperform | Hold |
| May 17, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Protagonist Therapeutics's last stock rating was published by Cowen & Co. on Oct 14, 2024. The company gave PTGX a "Buy" rating, the same as its previous rate.
Protagonist Therapeutics Financial Forecast
Protagonist Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 23 | Dec 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $859.00K | $25.72M | $8.62M | $10.29M | $2.27M | $6.19M | $5.65M | $13.11M | $6.22M | $3.65M | $2.72M | $4.14M | $-8.19M | $1.56M | $10.78M |
| Avg Forecast | $48.50M | $14.67M | $23.30M | $14.52M | $61.17M | $3.11M | $3.14M | $262.50M | $60.00M | $2.00M | $3.33M | $460.00K | $21.18M | $5.07M | $1.74M | $5.17M | $1.50M | $2.70M | $2.87M | $2.95M | $1.48M | $4.23M | $4.83M | $11.20M | $4.89M | $8.68M |
| High Forecast | $108.85M | $32.92M | $52.30M | $33.07M | $136.86M | $6.99M | $7.05M | $589.16M | $134.66M | $4.49M | $7.48M | $460.00K | $21.18M | $5.07M | $1.74M | $5.17M | $1.50M | $2.70M | $2.87M | $2.95M | $1.48M | $4.23M | $4.83M | $11.20M | $4.89M | $10.42M |
| Low Forecast | $6.80M | $2.06M | $3.27M | $5.19M | $5.69M | $436.55K | $440.65K | $36.82M | $8.42M | $280.51K | $467.52K | $460.00K | $21.18M | $5.07M | $1.74M | $5.17M | $1.50M | $2.70M | $2.87M | $2.95M | $1.48M | $4.23M | $4.83M | $11.20M | $4.89M | $6.95M |
| # Analysts | 1 | 1 | 1 | 3 | 6 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.87% | 1.21% | 1.70% | 5.90% | 0.44% | 4.13% | 2.09% | 4.57% | 2.11% | 2.46% | 0.64% | 0.86% | -0.73% | 0.32% | 1.24% |
Protagonist Therapeutics's average Quarter revenue forecast for Dec 22 based on 1 analysts is $3.33M, with a low forecast of $467.52K, and a high forecast of $7.48M. PTGX's average Quarter revenue forecast represents a 288.05% increase compared to the company's last Quarter revenue of $859.00K (Jun 22).
Protagonist Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 23 | Dec 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 6 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-36.02M | $-36.52M | $-40.60M | $-20.28M | $-36.09M | $-33.10M | $-30.21M | $-23.37M | $-18.13M | $-7.12M | $-17.44M | $-19.00M | $-15.83M | $-15.87M | $-30.18M | $-13.33M | $-7.58M |
| Avg Forecast | $-48.50M | $-14.67M | $-23.30M | $-14.52M | $-61.17M | $-3.11M | $-3.14M | $-22.95M | $-60.00M | $-24.55M | $-34.17M | $-460.00K | $-26.26M | $-5.07M | $-1.74M | $-5.17M | $-24.60M | $-2.70M | $-2.87M | $-2.95M | $-18.17M | $-4.23M | $-4.83M | $-11.20M | $-13.56M | $-5.75M |
| High Forecast | $-6.80M | $-2.06M | $-3.27M | $-5.19M | $-5.69M | $-436.55K | $-440.65K | $-18.36M | $-8.42M | $-19.64M | $-27.34M | $-460.00K | $-21.00M | $-5.07M | $-1.74M | $-5.17M | $-19.68M | $-2.70M | $-2.87M | $-2.95M | $-14.54M | $-4.23M | $-4.83M | $-11.20M | $-10.85M | $-4.60M |
| Low Forecast | $-108.85M | $-32.92M | $-52.30M | $-33.07M | $-136.86M | $-6.99M | $-7.05M | $-27.54M | $-134.66M | $-29.46M | $-41.01M | $-460.00K | $-31.51M | $-5.07M | $-1.74M | $-5.17M | $-29.53M | $-2.70M | $-2.87M | $-2.95M | $-21.81M | $-4.23M | $-4.83M | $-11.20M | $-16.27M | $-6.90M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.47% | 1.07% | 88.26% | 0.77% | 7.12% | 18.99% | 5.84% | 0.95% | 6.71% | 2.48% | 5.91% | 1.05% | 3.74% | 3.29% | 2.69% | 0.98% | 1.32% |
undefined analysts predict PTGX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Protagonist Therapeutics's previous annual EBITDA (undefined) of $NaN.
Protagonist Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 23 | Dec 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 6 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | $-31.43M | $-31.29M | $-40.63M | $-20.75M | $-36.91M | $-33.80M | $-30.84M | $-24.00M | $-18.89M | $-7.76M | $-19.42M | $-20.08M | $-17.50M | $-16.41M | $-29.17M | $-14.10M | $-7.66M |
| Avg Forecast | $-16.06M | $-37.06M | $-31.38M | $-26.44M | $17.36M | $-35.67M | $-36.78M | $-24.11M | $3.31M | $-25.78M | $-34.95M | $-57.34M | $-27.57M | $-47.94M | $-41.07M | $-33.44M | $-25.26M | $-29.30M | $-37.55M | $-34.64M | $-19.21M | $-39.73M | $-43.32M | $-17.17M | $-14.34M | $-5.81M |
| High Forecast | $1.89M | $4.36M | $3.69M | $-15.03M | $1.79B | $4.20M | $4.33M | $-19.29M | $14.28M | $-20.63M | $-27.96M | $-57.34M | $-22.06M | $-47.94M | $-41.07M | $-33.44M | $-20.21M | $-29.30M | $-37.55M | $-34.64M | $-15.37M | $-39.73M | $-43.32M | $-17.17M | $-11.47M | $-4.65M |
| Low Forecast | $-42.04M | $-97.02M | $-82.14M | $-33.18M | $-989.34M | $-93.38M | $-96.27M | $-28.93M | $-7.66M | $-30.94M | $-41.94M | $-57.34M | $-33.09M | $-47.94M | $-41.07M | $-33.44M | $-30.31M | $-29.30M | $-37.55M | $-34.64M | $-23.05M | $-39.73M | $-43.32M | $-17.17M | $-17.21M | $-6.97M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.22% | 0.90% | 0.71% | 0.75% | 0.77% | 0.82% | 0.92% | 0.95% | 0.64% | 0.21% | 0.56% | 1.05% | 0.44% | 0.38% | 1.70% | 0.98% | 1.32% |
Protagonist Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PTGX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Protagonist Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 23 | Dec 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 6 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | $8.61M | $6.63M | $7.69M | $10.52M | $7.26M | $7.26M | $6.71M | $5.96M | $4.99M | $4.89M | $4.18M | $4.58M | $4.11M | $4.01M | $3.86M | $3.76M | $3.64M |
| Avg Forecast | $694.28M | $209.95M | $333.58M | $207.89M | $875.63M | $44.56M | $44.97M | $12.11M | $858.90M | $28.63M | $47.72M | $6.58M | $13.85M | $72.60M | $24.95M | $74.03M | $21.47M | $38.65M | $41.04M | $42.23M | $21.19M | $60.52M | $69.09M | $160.33M | $3.83M | $2.76M |
| High Forecast | $1.56B | $471.22M | $748.69M | $473.33M | $1.96B | $100.00M | $100.94M | $14.53M | $1.93B | $64.26M | $107.10M | $6.58M | $16.62M | $72.60M | $24.95M | $74.03M | $21.47M | $38.65M | $41.04M | $42.23M | $21.19M | $60.52M | $69.09M | $160.33M | $4.59M | $3.32M |
| Low Forecast | $97.38M | $29.45M | $46.79M | $74.25M | $81.43M | $6.25M | $6.31M | $9.69M | $120.47M | $4.02M | $6.69M | $6.58M | $11.08M | $72.60M | $24.95M | $74.03M | $21.47M | $38.65M | $41.04M | $42.23M | $21.19M | $60.52M | $69.09M | $160.33M | $3.06M | $2.21M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.30% | 0.14% | 1.17% | 0.76% | 0.10% | 0.29% | 0.09% | 0.28% | 0.13% | 0.12% | 0.10% | 0.22% | 0.07% | 0.06% | 0.02% | 0.98% | 1.32% |
Protagonist Therapeutics's average Quarter SG&A projection for Dec 23 is $858.90M, based on 3 Wall Street analysts, with a range of $120.47M to $1.93B. The forecast indicates a 9881.39% rise compared to PTGX last annual SG&A of $8.61M (Mar 23).
Protagonist Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 23 | Dec 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 6 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.62 | $-0.64 | $-0.83 | $-0.43 | $-0.77 | $-0.70 | $-0.69 | $-0.54 | $-0.48 | $-0.21 | $-0.59 | $-0.72 | $-0.63 | $-0.61 | $-1.18 | $-0.58 | $-0.36 |
| Avg Forecast | $-0.26 | $-0.60 | $-0.51 | $-0.43 | $0.28 | $-0.58 | $-0.60 | $3.37 | $0.05 | $-0.73 | $-0.67 | $-0.94 | $-0.54 | $-0.78 | $-0.67 | $-0.55 | $-0.57 | $-0.48 | $-0.61 | $-0.56 | $-0.69 | $-0.65 | $-0.71 | $-0.28 | $-0.59 | $-0.22 |
| High Forecast | $0.03 | $0.07 | $0.06 | $-0.24 | $28.94 | $0.07 | $0.07 | $8.81 | $0.23 | $0.09 | $0.08 | $-0.94 | $-0.54 | $-0.78 | $-0.67 | $-0.55 | $-0.57 | $-0.48 | $-0.61 | $-0.56 | $-0.69 | $-0.65 | $-0.71 | $-0.28 | $-0.59 | $-0.18 |
| Low Forecast | $-0.68 | $-1.57 | $-1.33 | $-0.54 | $-16.02 | $-1.51 | $-1.56 | $-0.40 | $-0.12 | $-1.90 | $-1.75 | $-0.94 | $-0.54 | $-0.78 | $-0.67 | $-0.55 | $-0.57 | $-0.48 | $-0.61 | $-0.56 | $-0.69 | $-0.65 | $-0.71 | $-0.28 | $-0.59 | $-0.26 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.85% | 0.96% | 0.89% | 0.80% | 0.98% | 1.04% | 1.26% | 0.95% | 1.00% | 0.34% | 1.04% | 1.04% | 0.97% | 0.86% | 4.21% | 0.99% | 1.64% |
According to undefined Wall Street analysts, Protagonist Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PTGX previous annual EPS of $NaN (undefined).
Protagonist Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $1.72 | $33.86 | 1868.60% | Buy |
| XFOR | X4 Pharmaceuticals | $0.34 | $3.67 | 979.41% | Buy |
| BDTX | Black Diamond Therapeutics | $2.43 | $14.75 | 507.00% | Buy |
| RLAY | Relay Therapeutics | $4.66 | $19.40 | 316.31% | Buy |
| ARVN | Arvinas | $22.69 | $71.00 | 212.91% | Buy |
| PLRX | Pliant Therapeutics | $12.73 | $39.71 | 211.94% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.37 | $7.00 | 195.36% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.62 | $38.80 | 184.88% | Buy |
| STOK | Stoke Therapeutics | $11.31 | $30.60 | 170.56% | Buy |
| TERN | Terns Pharmaceuticals | $5.60 | $14.25 | 154.46% | Buy |
| REPL | Replimune Group | $11.23 | $24.20 | 115.49% | Buy |
| SNDX | Syndax Pharmaceuticals | $15.95 | $34.30 | 115.05% | Buy |
| IDYA | IDEAYA Biosciences | $25.54 | $46.58 | 82.38% | Buy |
| MRUS | Merus | $42.93 | $77.13 | 79.66% | Buy |
| KURA | Kura Oncology | $15.91 | $26.00 | 63.42% | Buy |
| AKRO | Akero Therapeutics | $30.64 | $46.00 | 50.13% | Buy |
| RNA | Avidity Biosciences | $43.65 | $54.50 | 24.86% | Buy |
| PTGX | Protagonist Therapeutics | $40.65 | $50.00 | 23.00% | Buy |
| HOOK | HOOKIPA Pharma | $2.72 | $3.00 | 10.29% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $57.07 | $60.63 | 6.24% | Buy |
| VRNA | Verona Pharma | $38.85 | $33.86 | -12.84% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |